| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 18, 2004
From the Departments of Regenerative Medicine and Tissue Engineering (N.N., T.I., T.I., S.M.), Internal Medicine (N.N., M.Y., K.M.), Biochemistry (K.K., T.T.), and Cardiac Physiology (Y.M., T.F., H.M.), National Cardiovascular Center Research Institute, Osaka; the Cardiovascular Division (M.U.), Kansai Rosai Hospital, Hyogo; the Tissue Engineering Research Center (H.O.), National Institute of Advanced Industrial Science and Technology, Hyogo; and the Department of Cardiovascular Surgery (S.K.), National Cardiovascular Center, Osaka, Japan. * To whom correspondence should be addressed. E-mail: nnagaya{at}ri.ncvc.go.jp.
Background--Pluripotent mesenchymal stem cells (MSCs) differentiate into a variety of cells, including cardiomyocytes and vascular endothelial cells. However, little information is available about the therapeutic potency of MSC transplantation in cases of dilated cardiomyopathy (DCM), an important cause of heart failure. Methods and Results--We investigated whether transplanted MSCs induce myogenesis and angiogenesis and improve cardiac function in a rat model of DCM. MSCs were isolated from bone marrow aspirates of isogenic adult rats and expanded ex vivo. Cultured MSCs secreted large amounts of the angiogenic, antiapoptotic, and mitogenic factors vascular endothelial growth factor, hepatocyte growth factor, adrenomedullin, and insulin-like growth factor-1. Five weeks after immunization, MSCs or vehicle was injected into the myocardium. Some engrafted MSCs were positive for the cardiac markers desmin, cardiac troponin T, and connexin-43, whereas others formed vascular structures and were positive for von Willebrand factor or smooth muscle actin. Compared with vehicle injection, MSC transplantation significantly increased capillary density and decreased the collagen volume fraction in the myocardium, resulting in decreased left ventricular end-diastolic pressure (11±1 versus 16±1 mm Hg, P<0.05) and increased left ventricular maximum dP/dt (6767±323 versus 5138±280 mm Hg/s, P<0.05). Conclusions--MSC transplantation improved cardiac function in a rat model of DCM, possibly through induction of myogenesis and angiogenesis, as well as by inhibition of myocardial fibrosis. The beneficial effects of MSCs might be mediated not only by their differentiation into cardiomyocytes and vascular cells but also by their ability to supply large amounts of angiogenic, antiapoptotic, and mitogenic factors.
Revised on April 28, 2005
Accepted on May 10, 2005
Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy
Noritoshi Nagaya MD*,
This article has been cited by other articles:
![]() |
R. W. Grauss, J. van Tuyn, P. Steendijk, E. M. Winter, D. A. Pijnappels, B. Hogers, A. C. Gittenberger-De Groot, R. van der Geest, A. van der Laarse, A. A.F. de Vries, et al. Forced Myocardin Expression Enhances the Therapeutic Effect of Human Mesenchymal Stem Cells After Transplantation in Ischemic Mouse Hearts Stem Cells, April 1, 2008; 26(4): 1083 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Hahn, H.-J. Cho, H.-J. Kang, T.-S. Kim, M.-H. Kim, J.-H. Chung, J.-W. Bae, B.-H. Oh, Y.-B. Park, and H.-S. Kim Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 933 - 943. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hayashi, S. Tsuji, M. Tsujii, T. Nishida, S. Ishii, H. Iijima, T. Nakamura, H. Eguchi, E. Miyoshi, N. Hayashi, et al. Topical transplantation of mesenchymal stem cells accelerates gastric ulcer healing in rats Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G778 - G786. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gandia, A. Arminan, J. M. Garcia-Verdugo, E. Lledo, A. Ruiz, M D. Minana, J. Sanchez-Torrijos, R. Paya, V. Mirabet, F. Carbonell-Uberos, et al. Human Dental Pulp Stem Cells Improve Left Ventricular Function, Induce Angiogenesis, and Reduce Infarct Size in Rats with Acute Myocardial Infarction Stem Cells, March 1, 2008; 26(3): 638 - 645. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sasaki, R. Abe, Y. Fujita, S. Ando, D. Inokuma, and H. Shimizu Mesenchymal Stem Cells Are Recruited into Wounded Skin and Contribute to Wound Repair by Transdifferentiation into Multiple Skin Cell Type J. Immunol., February 15, 2008; 180(4): 2581 - 2587. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Molina, J. Palma, D. Gupta, D. Torres, J. P. Gaughan, S. Houser, and M. Macha Improvement in hemodynamic performance, exercise capacity, inflammatory profile, and left ventricular reverse remodeling after intracoronary delivery of mesenchymal stem cells in an experimental model of pressure overload hypertrophy. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 292 - 299. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yanagawa, M. Kataoka, S. Ohnishi, M. Kodama, K. Tanaka, Y. Miyahara, H. Ishibashi-Ueda, Y. Aizawa, K. Kangawa, and N. Nagaya Infusion of adrenomedullin improves acute myocarditis via attenuation of myocardial inflammation and edema Cardiovasc Res, October 1, 2007; 76(1): 110 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Simpson, H. Liu, T.-H. M. Fan, R. Nerem, and S. C. Dudley Jr. A Tissue Engineering Approach to Progenitor Cell Delivery Results in Significant Cell Engraftment and Improved Myocardial Remodeling Stem Cells, September 1, 2007; 25(9): 2350 - 2357. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Breitbach, T. Bostani, W. Roell, Y. Xia, O. Dewald, J. M. Nygren, J. W. U. Fries, K. Tiemann, H. Bohlen, J. Hescheler, et al. Potential risks of bone marrow cell transplantation into infarcted hearts Blood, August 15, 2007; 110(4): 1362 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Song, W. Chang, S. Lim, H.-S. Seo, C. Y. Shim, S. Park, K.-J. Yoo, B.-S. Kim, B.-H. Min, H. Lee, et al. Tissue Transglutaminase Is Essential for Integrin-Mediated Survival of Bone Marrow-Derived Mesenchymal Stem Cells Stem Cells, June 1, 2007; 25(6): 1431 - 1438. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ventura, S. Cantoni, F. Bianchi, V. Lionetti, C. Cavallini, I. Scarlata, L. Foroni, M. Maioli, L. Bonsi, F. Alviano, et al. Hyaluronan Mixed Esters of Butyric and Retinoic Acid Drive Cardiac and Endothelial Fate in Term Placenta Human Mesenchymal Stem Cells and Enhance Cardiac Repair in Infarcted Rat Hearts J. Biol. Chem., May 11, 2007; 282(19): 14243 - 14252. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ohnishi, T. Yasuda, S. Kitamura, and N. Nagaya Effect of Hypoxia on Gene Expression of Bone Marrow-Derived Mesenchymal Stem Cells and Mononuclear Cells Stem Cells, May 1, 2007; 25(5): 1166 - 1177. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Togel, K. Weiss, Y. Yang, Z. Hu, P. Zhang, and C. Westenfelder Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1626 - F1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Seth, R. Narang, B. Bhargava, R. Ray, S. Mohanty, G. Gulati, L. Kumar, K. S. Reddy, P. Venugopal, and AIIMS Cardiovascular Stem Cell Study Group Percutaneous Intracoronary Cellular Cardiomyoplasty for Nonischemic Cardiomyopathy: Clinical and Histopathological Results: The First-in-Man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) Trial J. Am. Coll. Cardiol., November 10, 2006; (2006) j.jacc.2006.07.057v1. [Full Text] [PDF] |
||||
![]() |
A. Akgul and G. P Noon Comparison of mast cell properties and myocardial structure in dilated and ischemic hearts under mechanical circulatory support. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 637 - 637. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |